Company / R&D Expense
Nuo Therapeutics, Inc. R&D Expense History
FY2011-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$1.3M
FY2017
5-year range
$1.0M / $4.0M
FY2013-FY2017
Trend
+30.8%
vs FY2016
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense returned to growth in FY2017 after 2 years of decline, reaching $1M.
Based on SEC 10-K filings.
$1M in FY2017 with a 5-year CAGR of -17.1%.
Declined from $3M to $1M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -31.0%
- 5-Year CAGR
- -17.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -17.1%, indicating a declining trend.
- In FY2017, r&d expense increased 30.8% year-over-year.
- Peak r&d expense was recorded in FY2014.
- Lowest r&d expense in the period was in FY2011.
Company context
Key Data Points
- Altman Z-Score -45.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2017 | $1.3M | +30.8% |
| FY2016 | $1.0M | -60.2% |
| FY2015 | $2.6M | -36.8% |
| FY2014 | $4.0M | +6.3% |
| FY2013 | $3.8M | +12.2% |
| FY2012 | $3.4M | +3350.3% |
| FY2011 | $98.1K | - |
As of FY2017 · SEC 10-K · Updated Jun 29, 2026